one of the reasons sales are stalling for kombucha. smaller bottle than GT and higher price, with less promotion and marketing and product information.
good read. the ceo is from the early 2000s. she is trying the same strategies and thinks the market is the same.
like the pbj soda. know what is in it? i dont either. they dont publish ingredients on the website for many products. seems it too hard. tough to maintain a website with a staff of only 27 people and millions of dollars in losses.
you have to prove efficacy to the fda for diagnostic lab tests. holy #$%$. you think a lab can announce we can predict cancer with this blood test and then go a sell the test? and the fda goes hmmm, sure sounds good. taking those breasts off are ya? cool with us.
i have owned mygn stock for 15 years. performance has been fair. not good. fair. the stock is not near its highs from 14 years ago. it is not in the top 1000 best stocks to have owned for the last ten years i pretty sure. so i am not so impressed on that front. i think the company can do well going forward. i DO NOT think they have done a good job educating people, marketing or expanding internationally. maybe that will change. the angelina jolie press was fortunate and then wasted. utterly wasted. a crime that she was not brought on as a spokesperson for cancer screening. and they are blowing prolaris at this point as well. no one could research the test reasonably and understand it. not even a doctor.
"Myriad’s Prolaris is a genomic test applied to predict cancer-specific disease progression and mortality based on an analysis of 46 cell cycle progression genes. It is the only test available that shows prognostic value in both pre and post prostatectomy settings. Currently, it is approved by the FDA for use in low-risk men with a Gleason score of 6, as well as for post-prostatectomy patients who are categorized in the high-risk zone for prostate cancer recurrence." from mygn press release.
i assume you just make up your facts and manufacture outrage.
not much to say?
1. bargain. before you type in all caps, try and be correct. you are actually entirely incorrect. of course they need fda approval to market the tests. good lord.
2. newt. really: Prolaris has been proven to predict prostate cancer-specific disease progression in 4 published clinical trials. you made my point exactly. mygn says its effective, so move along.... not x more effective than another test. a cheaper test. a different protocol. the language is laughable. its like marketing fluff.
you still have not said anything AT ALL about the effectiveness of the test vs. current protocols. a 30% reduction in aggressive therapy relates to nothing at all. it is not how fda trial results are measured. wow. go through the prolaris website. find data.
that is the worst post i have ever seen from you.
no one really understands the benefits and data on prolaris, so trust your urologist. he has access to the secret data. #$%$? translation: you can't find information explaining prolaris either.
it would appear he does not have so much faith in AIRT's business. it is like a mutual fund here. less than $1 to the 52 week lows and he invests in interactive marketing and ads. clearly he does not see a way to spend the money on the main business so he tied it up in another utterly unrelated business with little liquidity but paying top dollar. a PE of 38! tempting....
of course not. why would they be? they can go for several more years, unless they get dropped by a major retailer. then the economy of scale is fully gone. personally, i think walmart will drop the line. they simply can not be selling much soda, because no one is selling much of this product.
i have problem with them doing flavors like this, provided it is done at a profit and with some degree of pride. unfortunately the soda itself is a hot mess and completely contrary to trend. a parent might allow a child to buy one as a treat. not a way to build a business. and as i have been saying, they make soda for children. here finally, jennifer clueless shows that is exactly what they are doing. building a brand targeted at kids with chemicals for ingredients. back to school with chemical colored fizzy water. and they think this is "cool"
that is obviously not the conclusion of the market. and you only know what you have been told by biased sources. if it was so obviously better, it would have been adopted. something clearly!!!! is holding back adoption. it is not clear what that is.
the fantasy of the short squeeze. steady upward move? on what chart is there a steady upward move?
the shorts are not scared at all here. they have had a million chances to cover. and each of the last earnings saw the stocks fall significantly. if the market falls 1000 points, mygn will fall faster than the market. no question at all. the stock is range-bound with the short term trend being lower and the intermediate term being up. it is far from its all time highs, now 13 years ago. without the share buy backs, the stock would be in the low 30s i would guess. so the organic business has been ok, not great. the guidance was not great either. as a long term buy, i think mygn will do well. over the next 3 months? i dont expect much. the medicare/prolaris issue being resolved would provide some clarity.
the delay may stem from the same confusion the website presents. why is prolaris important? no one has answered this yet on this board. the lack of clarity is concerning.
at some point someone with a pedigree is going to tell them convincingly that their products - artificially flavored, colored and preserved soda in kids flavors, is a giant market loser. the clown - or clowns - who decided to market a natural soda, but forgot to publish the ingredients might get fired too. it would be nice to see management hired that is content to manage the company as opposed to going hiking with their dog and gawking at fiats.
why would anyone hold after the earnings report? it was poor. it gave no guidance as to the direction of the company or its business. it looks like a company that exists to pay the executives salaries. i have posted multiple times how there is no apparent change and no apparent direction. the operations actually posted a loss for the quarter. so i see no reason why the stock should not return to $6-$7 a share, where it historically goes when their sales weaken.
i have been looking at this for a long time, but i have not purchased. i do not think they are viable. they are not winning over an increasing number of doctors and surgeons do not like switching or experimenting much. they seem to me to be on the road to losing another 20 million over the next couple years. if i were a salesperson, i do not think i would be with the company long. so hard to sell it seems in a very busy market. the good salespeople are going to go where the money is. with tax loss selling and dilution coming, i see 20 cents this year. if i was putting in equity i would absolutely want shares i could sell at 25 cents at the least.
and by the way. INGREDIENTS: CARBONATED WATER, INVERTED CANE SUGAR, CITRIC ACID, NATURAL AND ARTIFICIAL FLAVORS, SODIUM BENZOATE (AS PRESERVATIVE), MODIFIED FOOD STARCH, POTASSIUM SORBATE
that is fact. not bashing. the stock chart for the last 8 years is fact. not bashing. not 8 months. 8 years of failure. at some point they either close the doors, sell it someone else, or hire someone with a clue.
ok. it was statistically significant. you make my point. where on the website or elsewhere in PR or otherwise is it explained what the benefit is over current protocols. just because it is SS doesnt mean anything. other tests could be more significant. cheaper tests. who knows. when i say mygn has a marketing problem, this is what i mean among other things. so is it a critical advance or not? we do not see medicare rushing to approve reimbursement do we? the website for prolaris goes wildly out of the way to avoid all but the most bland statements.
dude. that is entirely inappropriate and may be actionable by Reed. if you call a company a scam, you better be prepared with some evidence or you risk liability yourself.